Loading clinical trials...

Liver and the Spleen Stifness in Adult Patients With Gaucher's Disease Using Ultrasound Shear Wave Elastography | Clinical Trials | Clareo Health

TERMINATED

Liver and the Spleen Stifness in Adult Patients With Gaucher's Disease Using Ultrasound Shear Wave Elastography

Prospective Study: Shear-Wave Elastography of the Liver and the Spleen in Adult Patients With Gaucher's Disease

NCT03896607•HaEmek Medical Center, Israel

View on ClinicalTrials.gov

Summary

The investigated cohort will examine liver and spleen fibrosis in patients with Gaucher Disease(GD) by using Shear Wave Elastography- SWE to evaluation fibrosis of the tissue and to check the correlation of fibrosis with the biomarkers of disease severity.

Detailed Description

To assess liver and spleen stiffness measurement using Shear Wave Elastography-SWE and evaluate liver and spleen fibrosis in patients with Gaucher Disease. To compare the elastography with the biomarkers that taken at the GD haematology clinic and to check the correlation with severity of liver and spleen fibrosis. SWE is a safe with diagnostic accuracy regarding the liver (\& Spleen) fibrosis. Estimating spleen fibrosis is an innovative approach in liver disease and Gaucher. The evaluation of fibrosis with this relatively new and safe method could avoid complications and invasive procedure in GD patients .

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients with Gaucher disease over the age of 18 years.
•2. Patients able to sign informed consent form.
•3. Women are not pregnant.
•4. Patients who read and understood the contents of the consent form and gave their written consent to participate in the study.

Exclusion Criteria

•1. Participants under the age of 18.
•2. Pregnant women.
•3. Participants are unable to sign an informed consent form.
•4. Participants with known liver disease not associated with Gaucher disease such as liver cirrhosis, patients with HBV, HBC or liver cirrhosis.

Locations (1)

HaEmek Medical Center

Afula, Northern District, Israel

Key Dates

Start Date

March 30, 2019

Primary Completion Date

October 31, 2022

Completion Date

October 31, 2022

Last Updated

March 6, 2023

Enrollment

ACTUAL participants

Conditions

Gaucher DiseaseLiver FibrosisSpleen; Fibrosis

Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis

NCT04429100

Liver Fibrosis

View study

RECRUITINGPHASE3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444

Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver Fibrosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Liver and the Spleen Stifness in Adult Patients With Gaucher's Disease Using Ultrasound Shear Wave Elastography

Inclusion Criteria

Exclusion Criteria

Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma

Institutional Registry of Rare Diseases

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

A Long-term Follow-up Study of Gaucher Disease